Dr Kristin Diane Hudacek, MD | |
20730 Valley Green Dr, Cupertino, CA 95014-1704 | |
(408) 783-4000 | |
Not Available |
Full Name | Dr Kristin Diane Hudacek |
---|---|
Gender | Female |
Speciality | Dermatology |
Location | 20730 Valley Green Dr, Cupertino, California |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1275760910 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207N00000X | Dermatology | A126296 (California) | Primary |
Entity Name | Permanente Medical Group Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that the Company has initiated patient dosing in a Phase II clinical trial of ACH-1625 for the treatment of hepatitis C virus (HCV) infection. ACH-1625 is a potent small molecule inhibitor of HCV protease, an enzyme necessary for viral replication. The drug candidate was discovered and is being advanced by Achillion.
Advaxis, Inc., a leader in developing cancer immunotherapies, announced today that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration Office of Orphan Products Development (OOPD) for ADXS-HPV, its lead immunotherapy drug candidate, for the treatment of Stage II-IV invasive cervical cancer.
Riga, Latvia will be the venue for the 3rd Baltic Congress of Osteoporosis which will take place on September 3-4, 2010. The congress, to be held in English, is jointly organized by the Latvian Osteoporosis and Bone Metabolism Diseases Association, Lithuanian Osteoporosis Foundation, Lithuanian Association of Metabolic Bone Diseases and the Estonian Osteoporosis Society.
Demonstrating the fortitude to address a challenging healthcare environment, president and C.E.O. Steven D. Sonenreich has led Mount Sinai Medical Center to financial stability and successfully reinforced its image as a healthcare leader. The most recent audit posted on March 26 reports nearly $14 million in profit for 2009.
Men with prostate cancers under the NHS would soon get non-invasive MRI scans for detections after a health body (National Institute for Health and Care Excellence or NICE) has given its approval. At present the MRI scans for detection have undergone pilot trials in three areas only and may soon be available all over Wales.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Kristin Diane Hudacek, MD 333 Main St, Apt 327, Redwood City, CA 94063-1762 Ph: (267) 320-9261 | Dr Kristin Diane Hudacek, MD 20730 Valley Green Dr, Cupertino, CA 95014-1704 Ph: (408) 783-4000 |
News Archive
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that the Company has initiated patient dosing in a Phase II clinical trial of ACH-1625 for the treatment of hepatitis C virus (HCV) infection. ACH-1625 is a potent small molecule inhibitor of HCV protease, an enzyme necessary for viral replication. The drug candidate was discovered and is being advanced by Achillion.
Advaxis, Inc., a leader in developing cancer immunotherapies, announced today that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration Office of Orphan Products Development (OOPD) for ADXS-HPV, its lead immunotherapy drug candidate, for the treatment of Stage II-IV invasive cervical cancer.
Riga, Latvia will be the venue for the 3rd Baltic Congress of Osteoporosis which will take place on September 3-4, 2010. The congress, to be held in English, is jointly organized by the Latvian Osteoporosis and Bone Metabolism Diseases Association, Lithuanian Osteoporosis Foundation, Lithuanian Association of Metabolic Bone Diseases and the Estonian Osteoporosis Society.
Demonstrating the fortitude to address a challenging healthcare environment, president and C.E.O. Steven D. Sonenreich has led Mount Sinai Medical Center to financial stability and successfully reinforced its image as a healthcare leader. The most recent audit posted on March 26 reports nearly $14 million in profit for 2009.
Men with prostate cancers under the NHS would soon get non-invasive MRI scans for detections after a health body (National Institute for Health and Care Excellence or NICE) has given its approval. At present the MRI scans for detection have undergone pilot trials in three areas only and may soon be available all over Wales.
› Verified 7 days ago